Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 23, 2001

View Archived Issues

Helinx technology successfully inactivates Trypanosoma cruzi

Antex concludes Phase I of SBIR grant from U.S. Army

Approval of Xeloda for treatment of breast cancer recommended in E.U.

R-105266 emerges from preclinical testing as safe and effective antiulcer agent

Clinical development update provided for CYC-202, a CDK2 inhibitor

Long-term tamsulosin has sustained efficacy, safety in LUTS/BPH

Novel products moving successfully through the pipeline at Millennium

Potentiation of insulin action by two different IR activators in insulin-resistant cells

Therapeutic efficacy demonstrated for selective ETA receptor antagonist in rat stroke model

Biogen highlights Q3 developments

Ariad presents a new small-molecule antitumor candidate targeting PTEN-deficient cancers

Vivus updates product pipeline

PARS inhibitors such as PJ-34 may be suitable for the therapy of septic shock

Cell Genesys commences phase II trial of GVAX vaccine for pancreatic cancer

Significant beneficial effects reported for PARP inhibitor in animal model of myocardial infarction

CPMP lifts Serdolect suspension; Lundbeck moves forward with postmarketing studies

Sangamo achieves first milestone in ZFP therapeutics program

Phase II trials of new treatment for atrial fibrillation set to begin

New agents for pain and inflammation designed at AstraZeneca

Cathepsin inhibitors from Ono particularly useful for inhibiting bone resorption

Hypoglycemic and hypolipidemic agents described by Takeda in recent patent

Synthesis and use of heterocyclic tyrosine kinase inhibitors for cancer, etc.

AstraZeneca patents new chemokine receptor modulators for psoriasis, COPD

MMP inhibitors and use in arthritis, atherosclerosis and COPD

Azign and the Center for Clinical and Basic Research to validate genes for obesity and diabetes

Curis receives third market approval for regeneration product

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 29, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...
Plasticity, properly parsed, provides psychiatric platform
BioWorld
If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...